Please login to the form below
Nuplazid
This page shows the latest Nuplazid news and features for those working in and with pharma, biotech and healthcare.
Acadia’s Nuplazid misses the mark in major depressive disorder trial
Nuplazid was also found to be generally safe to use, with the most common side effects including diarrhoea, dry mouth and headache. ... In this trial, Nuplazid was unable to show a significant improvement compared to placebo on the widely-used Positive
Latest news
-
Acadia’s drive to extend use of Nuplazid hits a wall
Shares in company down. Acadia Pharmaceutical’s Nuplazid was the first-ever drug to be approved to treat psychosis associated with Parkinson’s disease, but the company’s hopes of extending ... Nuplazid (pimavanserin) is Acadia’s only approved
-
Nuplazid backed by FDA panel as first-ever Parkinson's psychosis drug
Some atypical antipsychotic medicines are used to treat more advanced cases of PDP but - unlike Nuplazid - run the risk of aggravating motor symptoms. ... The company is also working on follow-up indications for Nuplazid, including clinical programmes in
More from news
Approximately 3 fully matching, plus 0 partially matching documents found.
Latest appointments
-
Srdjan Stankovic joins Acadia Pharmaceuticals
efforts to explore the full potential of Nuplazid to treat patients suffering from additional CNS disorders.” . ... I look forward to leading the team in advancing the promising development programmes with Nuplazid.".
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- AZ strengthens Daiichi Sankyo partnership with new ADC deal
- New study identifies drugs that are safe to use in COVID-19 treatment
- AbbVie, Amgen and Takeda team up for joint COVID-19 trial
- How will the events and exhibitions industry change post-Coronavirus?
- AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies
- Eli Lilly begins COVID-19 prevention trial in nursing homes
- Porterhouse Medical Group joins imc group
- Biogen pays Denali $1bn upfront for Parkinson’s disease programme
- Tecentriq combo fails in advanced triple negative breast cancer
- Bristol-Myers Squibb’s revenues rise on Celgene acquisition
- Socially distanced strategising
- Artificial Intelligence in Digital Therapeutics
PMHub
Wordbird
Wordbird is a healthcare communications agency with creative, compelling copy at its heart....
Latest intelligence
- Virtual Engagement At Porterhouse: Reflections on the past few months
- A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
- July 2020: diversity and inclusion in clinical trials round-up
- COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
- Medical Device Clinical Trials 2020
- In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Quick links
Infographics
